These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 30036254)

  • 1. Long-term Survival and Excellent Response to Repeated 177Lu-Prostate-Specific Membrane Antigen 617 Radioligand Therapy in a Patient With Advanced Metastatic Castration-Resistant Prostate Cancer.
    Roll W; Bräuer A; Weckesser M; Bögemann M; Rahbar K
    Clin Nucl Med; 2018 Oct; 43(10):755-756. PubMed ID: 30036254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Excellent Response to 177Lu-PSMA-617 Radioligand Therapy in a Patient With Advanced Metastatic Castration Resistant Prostate Cancer Evaluated by 68Ga-PSMA PET/CT.
    Roll W; Bode A; Weckesser M; Bögemann M; Rahbar K
    Clin Nucl Med; 2017 Feb; 42(2):152-153. PubMed ID: 27922871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617.
    Schlenkhoff CD; Knüpfer E; Essler M; Ahmadzadehfar H
    Clin Nucl Med; 2016 Jul; 41(7):572-3. PubMed ID: 26909718
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Heinzel A; Boghos D; Mottaghy FM; Gaertner F; Essler M; von Mallek D; Ahmadzadehfar H
    Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1054-1062. PubMed ID: 30697649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving
    Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A
    J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response assessment using
    Grubmüller B; Senn D; Kramer G; Baltzer P; D'Andrea D; Grubmüller KH; Mitterhauser M; Eidherr H; Haug AR; Wadsak W; Pfaff S; Shariat SF; Hacker M; Hartenbach M
    Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1063-1072. PubMed ID: 30569186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
    Baum RP; Kulkarni HR; Schuchardt C; Singh A; Wirtz M; Wiessalla S; Schottelius M; Mueller D; Klette I; Wester HJ
    J Nucl Med; 2016 Jul; 57(7):1006-13. PubMed ID: 26795286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes of
    Barber TW; Singh A; Kulkarni HR; Niepsch K; Billah B; Baum RP
    J Nucl Med; 2019 Jul; 60(7):955-962. PubMed ID: 30683770
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
    Yadav MP; Ballal S; Bal C; Sahoo RK; Damle NA; Tripathi M; Seth A
    Clin Nucl Med; 2020 Jan; 45(1):19-31. PubMed ID: 31789908
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Bräuer A; Grubert LS; Roll W; Schrader AJ; Schäfers M; Bögemann M; Rahbar K
    Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1663-1670. PubMed ID: 28624848
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Zang J; Liu Q; Sui H; Wang R; Jacobson O; Fan X; Zhu Z; Chen X
    J Nucl Med; 2020 Dec; 61(12):1772-1778. PubMed ID: 32358086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation Dosimetry for
    Okamoto S; Thieme A; Allmann J; D'Alessandria C; Maurer T; Retz M; Tauber R; Heck MM; Wester HJ; Tamaki N; Fendler WP; Herrmann K; Pfob CH; Scheidhauer K; Schwaiger M; Ziegler S; Eiber M
    J Nucl Med; 2017 Mar; 58(3):445-450. PubMed ID: 27660138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with
    Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M
    Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a Prospective Phase 2 Pilot Trial of
    Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM
    Clin Genitourin Cancer; 2019 Feb; 17(1):15-22. PubMed ID: 30425003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for
    Thang SP; Violet J; Sandhu S; Iravani A; Akhurst T; Kong G; Ravi Kumar A; Murphy DG; Williams SG; Hicks RJ; Hofman MS
    Eur Urol Oncol; 2019 Nov; 2(6):670-676. PubMed ID: 31412006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis.
    Kim YJ; Kim YI
    Clin Nucl Med; 2018 Oct; 43(10):728-734. PubMed ID: 30059428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The
    Maffey-Steffan J; Scarpa L; Svirydenka A; Nilica B; Mair C; Buxbaum S; Bektic J; von Guggenberg E; Uprimny C; Horninger W; Virgolini I
    Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):695-712. PubMed ID: 31776632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of [68Ga]Ga-PSMA PET/CT for therapy response assessment of [177Lu]Lu-PSMA radioligand therapy in metastasized castration refractory prostate cancer and correlation with survival.
    Kurth J; Kretzschmar J; Aladwan H; Heuschkel M; Gummesson A; Bergner C; Kundt G; Hakenberg OW; Krause BJ; Schwarzenböck SM
    Nucl Med Commun; 2021 Nov; 42(11):1217-1226. PubMed ID: 34424870
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Zhang J; Kulkarni HR; Singh A; Schuchardt C; Niepsch K; Langbein T; Baum RP
    J Nucl Med; 2019 Nov; 60(11):1579-1586. PubMed ID: 30850499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of whole-body tumour burden on [68Ga]PSMA-11 PET/CT for response assessment of [177Lu]PSMA-617 radioligand therapy: a retrospective analysis of serum PSA level and imaging derived parameters before and after two cycles of therapy.
    Michalski K; Mix M; Meyer PT; Ruf J
    Nuklearmedizin; 2019 Dec; 58(6):443-450. PubMed ID: 31724145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.